Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, United States.

This email address is being protected from spam bots, you need Javascript enabled to view it

Lower urinary tract symptoms (LUTS), the overactive bladder syndrome (OAB), and detrusor overactivity (DO) are all conditions that can have major effects on quality of life and social functioning. Antimuscarinic drugs are first-line treatment -- they often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, and alternatives are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters involved has sparked interest in both peripheral and central modulation of LUTS/OAB/DO pathophysiology. There may be several new possibilities to treat LUTS/OAB/DO. For example, beta(3)-adrenoceptor (AR) agonists (mirabegron), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil, vardenafil), combinations (alpha(1)-AR antagonist + antimuscarinic), and drugs with a central mode of action (tramadol, gabapentin) all have positive proof of concept documented in randomized, controlled trials. Which of these therapeutic principles will be developed to become clinically useful treatments remain to be established.

Written by:
Andersson KE.   Are you the author?

Reference:
Discov Med. 2009 Oct;8(42):118-24.

PubMed Abstract
PMID:19833057

UroToday.com Overactive Bladder (OAB) Section

Please log-in or register in order to submit comments.

Powered by AkoComment!